About: Entrada del virus de la inmunodeficiencia humana en las células: mecanismos y posibilidades terapéuticas

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Entrada del virus de la inmunodeficiencia humana en las células: mecanismos y posibilidades terapéuticas Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Entrada del virus de la inmunodeficiencia humana en las células: mecanismos y posibilidades terapéuticas
Creator	Briz, Verónica Poveda, Eva Soriano, Vicente
Source	Elsevier; PMC
abstract	La entrada del virus de la inmunodeficiencia humana (VIH) en la célula es la primera etapa del ciclo de replicación viral y una diana clave en la exploración de nuevos antirretrovirales. El mejor conocimiento de los mecanismos que se suceden con la entrada del VIH en las células que infecta ha permitido el desarrollo de moléculas que bloquean cada una de las etapas de la entrada vírica: unión de gp120 al receptor CD4; unión de gp120 a los correceptores de quimiocinas CCR5 y CXCR4, y fusión de las membranas viral y celular. Los inhibidores de la entrada del VIH son la última generación de antirretrovirales, de los cuales la enfuvirtida, un inhibidor de la fusión, ha sido el primero en comercializarse. Varios más se encuentran actualmente en fases avanzadas de desarrollo clínico y es de esperar que pronto contribuirán a mejorar el arsenal terapéutico frente al VIH. Human immunodeficiency virus (HIV) entry into cells is the first step in the viral replication cycle; which has been explored as a new therapeutic target; A better knowledge of the mechanisms involved in the entry process has led to the development of agents; which may inhibit each of the different steps of the viral entry process: attachment of the gp120 to the CD4 cell receptor; binding of the gp120 to CCR5 or CXCR4 coreceptors; and the fusion of viral and cell membranes; Entry inhibitors are the latest family of antiretroviral compounds; being enfuvirtide; a fusion inhibitor; the first approved; Several other entry inhibitors are currently in clinical development and hopefully soon will be part of the therapeutic armamentarium against HIV
has issue date	2006-03-31(xsd:dateTime)
bibo:doi	10.1157/13085735
bibo:pmid	16650368
has license	els-covid
sha1sum (hex)	0187705c2a09525d5cb71ec594b82e668255fcaf
schema:url	https://doi.org/10.1157/13085735
resource representing a document's title	Entrada del virus de la inmunodeficiencia humana en las células: mecanismos y posibilidades terapéuticas
has PubMed Central identifier	PMC7131321
has PubMed identifier	16650368
schema:publication	Medicina Clínica
resource representing a document's body	covid:0187705c2a09525d5cb71ec594b82e668255fcaf#body_text
is schema:about of	named entity 'virus' named entity 'REMAINS' named entity 'ACTIVE' named entity 'REPOSITORIES' named entity 'PERMISSIONS' named entity 'FUNDED' named entity 'HUMANA' named entity 'TERAP' named entity 'THESE' named entity 'VIRUS' named entity 'MEANS' named entity 'DATABASE' named entity 'RESOURCE' named entity 'COVID-19' named entity 'USE' named entity 'FORM' named entity 'UNRESTRICTED' named entity 'DEL' named entity 'LONG' named entity 'RESEARCH' named entity 'FREE' named entity 'RIGHTS' named entity 'ORIGINAL SOURCE' named entity 'CENTRE' named entity 'LAS' named entity 'Entrada' named entity 'gp120' named entity 'CXCR4' named entity 'CCR5' named entity 'gp120' named entity 'cepas' named entity 'CCR5' named entity 'CCR5' named entity 'CD4' named entity 'gp120' named entity 'gp120' named entity 'HR2' named entity 'gp120' named entity 'gp120' named entity 'gp120' named entity 'distinto' named entity 'gp120' named entity 'gp120' named entity 'gp41' named entity 'CXCR4' named entity 'N-terminal' named entity 'sinergia' named entity 'CD4' named entity 'infección' named entity 'la región' named entity 'CD4' named entity 'gp120' named entity 'CD4' named entity 'la entrada' named entity 'la entrada' named entity 'tienen' named entity 'gp120' named entity 'esta' named entity 'gp120' named entity 'HR2' named entity 'la entrada' named entity 'la región' named entity 'gp41' named entity 'CXCR4' named entity 'la entrada' named entity 'aclare' named entity 'simula' named entity 'gp120' named entity 'gp41' named entity 'gp120' named entity 'gp41' named entity 'cepas' named entity 'CCR5' named entity 'CCR5' named entity 'CCR5' named entity 'CD4' named entity 'simula' named entity 'infección' named entity 'CD4'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software